Skip to main content
NVDA-0.08%AAPL+0.03%MSFT+0.34%GOOGL+1.19%AMZN+0.29%TSM+2.95%SPCX+1.14%AVGO+4.00%TSLA+0.05%META-0.10%LLY+0.22%BRK-B-1.02%MU-0.26%SKHY+1.92%WMT-0.81%AMD+5.45%JPM+0.52%V-0.57%XOM-2.53%JNJ+0.91%ASMLa+2.80%MA-0.59%ABBV-0.10%INTC+3.61%1398.HK+2.15%CVX-1.59%0700.HK-0.31%CSCO+1.03%COST-1.30%ORCL+3.55%KO-1.64%UNH-0.08%PG-0.45%BAC+0.32%1816.HK+1.32%3988.HK+0.66%CAT+3.06%DELL+7.38%HD-0.28%PM+0.37%0857.HK-0.98%AMAT+2.15%AP2d+2.18%0939.HK+0.81%GE+3.20%1288.HK+0.60%LRCX+1.41%NVS+1.98%0005.HK-5.56%MS+1.91%USDJPY+0.69%EURUSD-0.64%AUDJPY+0.59%EURAUD-0.53%GBPUSD-0.51%USDCHF+0.46%NZDJPY+0.42%GBPTRY+0.41%GBPAUD-0.40%CADJPY+0.40%EURNZD-0.38%AUDCHF+0.37%GBPHKD+0.32%EURCAD-0.31%USDCAD+0.31%GBPMXN-0.28%USDTRY+0.28%NZDUSD-0.27%CHFJPY+0.25%GBPNZD-0.23%GBPCAD-0.21%AUDCAD+0.20%EURCHF-0.20%NZDCHF+0.19%GBPJPY+0.18%USDILS+0.16%AUDNZD+0.16%CADCHF+0.15%EURGBP-0.13%AUDUSD-0.11%EURJPY+0.07%NZDMXN+0.06%GBPCHF-0.06%NZDSGD+0.06%EURSGD+0.06%CHFSGD+0.05%USDCOP-0.04%USDCNH-0.04%USDHKD+0.03%NZDCAD+0.03%USDTHB-0.03%AUDSGD+0.03%USDSGD-0.01%USDZAR0.00%GBPSGD0.00%USDMXN0.00%SGDJPY0.00%USDSEK0.00%USDPLN0.00%USDDKK0.00%EURHKD0.00%EURCZK0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSEK0.00%AUDDKK0.00%CHFSEK0.00%GBPZAR0.00%EURNOK0.00%PLNJPY0.00%EURDKK0.00%USDNOK0.00%EURPLN0.00%CHFNOK0.00%NOKJPY0.00%USOIL-0.39%XNGUSD+0.32%XPTUSD+0.17%XAGUSD+0.13%GAGUSD+0.13%XAUUSD+0.09%GAUUSD+0.09%HG1-0.02%S10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+1.04%ETHUSD+23.96%USDTUSD+0.05%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT+0.82%ZECUSDT+6.31%DOGEUSD+20.65%XMRUSDT+1.57%LINKUSD+25.58%BCHUSDT+3.83%XLMUSD+0.53%UNIUSD-0.92%LTCUSD+17.89%SUIUSD+1.18%HBARUSDT-1.48%TONUSD+41.71%TAOUSDT+1.41%AAVEUSD-2.43%DOTUSDT-1.09%ICPUSDT-1.71%ONDOUSDT+0.80%WLDUSDT+0.14%ARBUSDT-1.18%JUPUSDT+0.66%INJUSDT-1.32%ATOMUSDT-1.19%STXUSDT-1.08%TIAUSDT-1.79%PYTHUSDT-2.78%FETUSDT+3.93%SEIUSDT+0.54%IMXUSDT-0.66%GRTUSDT+0.86%OPUSDT-0.20%WIFUSDT-0.61%IOTAUSDT+0.50%POLUSDT+0.99%AXSUSDT+0.83%EOSUSDT+1.14%FARTCOINUSDT+2.28%DYDXUSDT+2.47%GALAUSDT+1.56%ORDIUSDT+2.62%RONINUSDT+1.89%NOTUSDT+1.92%NVDA-0.08%AAPL+0.03%MSFT+0.34%GOOGL+1.19%AMZN+0.29%TSM+2.95%SPCX+1.14%AVGO+4.00%TSLA+0.05%META-0.10%LLY+0.22%BRK-B-1.02%MU-0.26%SKHY+1.92%WMT-0.81%AMD+5.45%JPM+0.52%V-0.57%XOM-2.53%JNJ+0.91%ASMLa+2.80%MA-0.59%ABBV-0.10%INTC+3.61%1398.HK+2.15%CVX-1.59%0700.HK-0.31%CSCO+1.03%COST-1.30%ORCL+3.55%KO-1.64%UNH-0.08%PG-0.45%BAC+0.32%1816.HK+1.32%3988.HK+0.66%CAT+3.06%DELL+7.38%HD-0.28%PM+0.37%0857.HK-0.98%AMAT+2.15%AP2d+2.18%0939.HK+0.81%GE+3.20%1288.HK+0.60%LRCX+1.41%NVS+1.98%0005.HK-5.56%MS+1.91%USDJPY+0.69%EURUSD-0.64%AUDJPY+0.59%EURAUD-0.53%GBPUSD-0.51%USDCHF+0.46%NZDJPY+0.42%GBPTRY+0.41%GBPAUD-0.40%CADJPY+0.40%EURNZD-0.38%AUDCHF+0.37%GBPHKD+0.32%EURCAD-0.31%USDCAD+0.31%GBPMXN-0.28%USDTRY+0.28%NZDUSD-0.27%CHFJPY+0.25%GBPNZD-0.23%GBPCAD-0.21%AUDCAD+0.20%EURCHF-0.20%NZDCHF+0.19%GBPJPY+0.18%USDILS+0.16%AUDNZD+0.16%CADCHF+0.15%EURGBP-0.13%AUDUSD-0.11%EURJPY+0.07%NZDMXN+0.06%GBPCHF-0.06%NZDSGD+0.06%EURSGD+0.06%CHFSGD+0.05%USDCOP-0.04%USDCNH-0.04%USDHKD+0.03%NZDCAD+0.03%USDTHB-0.03%AUDSGD+0.03%USDSGD-0.01%USDZAR0.00%GBPSGD0.00%USDMXN0.00%SGDJPY0.00%USDSEK0.00%USDPLN0.00%USDDKK0.00%EURHKD0.00%EURCZK0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSEK0.00%AUDDKK0.00%CHFSEK0.00%GBPZAR0.00%EURNOK0.00%PLNJPY0.00%EURDKK0.00%USDNOK0.00%EURPLN0.00%CHFNOK0.00%NOKJPY0.00%USOIL-0.39%XNGUSD+0.32%XPTUSD+0.17%XAGUSD+0.13%GAGUSD+0.13%XAUUSD+0.09%GAUUSD+0.09%HG1-0.02%S10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+1.04%ETHUSD+23.96%USDTUSD+0.05%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT+0.82%ZECUSDT+6.31%DOGEUSD+20.65%XMRUSDT+1.57%LINKUSD+25.58%BCHUSDT+3.83%XLMUSD+0.53%UNIUSD-0.92%LTCUSD+17.89%SUIUSD+1.18%HBARUSDT-1.48%TONUSD+41.71%TAOUSDT+1.41%AAVEUSD-2.43%DOTUSDT-1.09%ICPUSDT-1.71%ONDOUSDT+0.80%WLDUSDT+0.14%ARBUSDT-1.18%JUPUSDT+0.66%INJUSDT-1.32%ATOMUSDT-1.19%STXUSDT-1.08%TIAUSDT-1.79%PYTHUSDT-2.78%FETUSDT+3.93%SEIUSDT+0.54%IMXUSDT-0.66%GRTUSDT+0.86%OPUSDT-0.20%WIFUSDT-0.61%IOTAUSDT+0.50%POLUSDT+0.99%AXSUSDT+0.83%EOSUSDT+1.14%FARTCOINUSDT+2.28%DYDXUSDT+2.47%GALAUSDT+1.56%ORDIUSDT+2.62%RONINUSDT+1.89%NOTUSDT+1.92%
CT

Capricor Therapeutics, Inc. (CAPR)

NASDAQ • Healthcare

$6.1
+$0.35 (+6.3%)
Market closed

Last close at October 27, 2026 at 20:00 UTC

Open$5.79
Day Range$5.67 - $6.31
Avg. Volume (3M)3.5M
Market Cap$363.5M
52 Week Range
$2.96$40.37
Next EarningsIn 13 daysNov 9, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$129.4M
EPS (TTM)
-$2.45
ROA (TTM)
-35.1%
Current Ratio
7.35

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-21.6%Q1 2026-$0.62
-7.3%Q2 2026-$0.59
-18.9%Q3 2026-$0.7
Next

Nov 9

in 13 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -18.9%

Capricor Therapeutics’ loss per share widened versus expectations as EPS of -$0.70 trailed the -$0.59 estimate by -$0.11, based on preliminary results for the second fiscal quarter of 2026 (period ended June 30, 2026) reported August 14, 2026. Net income was a loss of roughly $40.7 million, down 57.2% year over year from a loss of about $25.9 million, alongside operating income of about -$42.9 million as the company continued spending across its cell and exosome-based therapeutics pipeline in rare diseases including Duchenne muscular dystrophy programs such as CAP-1002 and CAP-2003. Operating cash flow was negative roughly $31.5 million, reflecting cash usage during the quarter. For the next period, consensus calls for EPS of -$0.13 on revenue of $41.7 million.

Next report — what to expect

Capricor Therapeutics, Inc. (CAPR) reports next on November 9, 2026. Wall Street is looking for consensus EPS of -$0.138 on consensus revenue of $41.7 million. In recent history, Capricor has beaten EPS in 1 of 8 most recent quarters, making the EPS-versus-consensus result a key item to watch.

View full earnings history

About Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. is a small-cap biotechnology company listed on NASDAQ as CAPR that develops cell and exosome-based therapeutics. Its work centers on rare and serious diseases, with a pipeline built around programs aimed at Duchenne muscular dystrophy and other conditions with unmet medical needs.

Name
Capricor Therapeutics, Inc.
CEO
Linda Marbán
Website
www.capricor.com
Industry
Healthcare
Year Founded
1996
Employees
231

Today's Snapshot

AI-generated

CAPR closed 6.3% higher at 6.10, while its sector was flat. Kaos Capital, an activist investor, called for Capricor to replace its board over rising costs. CAPR reports earnings on 9 November.

Trading Volume

Above 10d avg 2.4M

3.1M

vs S&P 500 Today

Strong Outperformance

+5.58%

Updated: October 27, 2026 at 20:27 UTC

Technical Indicators

1 Buy1 Neutral6 Sell
CAPR’s technicals favor the downside as short- and medium-term averages sit well below long-term levels and momentum indicators are tilted negative. RSI is subdued and MACD is bearish while on‑balance volume and other trend measures reflect selling pressure; average true range is elevated as a percentage of price, indicating above-normal volatility amid the decline. Although pivot support lies below the current price, the combination of weak momentum, heavy long-term average divergence, and active selling tone points to a cautious stance. Technical takeaway: Sell.
All signals
  • EMA (5 indicators)$6.40 - $17.02
    Sell
  • RSI (14)37.25
    Neutral
  • Stochastic %K (14, 3, 3)8.26
    Buy
  • MACD Level (12, 26)-0.73
    Sell

Peers & Related Assets

IONSIonis Pharmaceuticals, Inc.
$43.96+1.2%
PTCTPTC Therapeutics, Inc.
$62.09+1.7%
EWTXEdgewise Therapeutics, Inc.
$39.53+0.9%
DYNDyne Therapeutics, Inc.
$16.94+7.8%
SRPTSarepta Therapeutics, Inc.
$18.89+5.1%
WVEWave Life Sciences Ltd.
$3.45+7.5%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.